The current investment opportunity consists of the buyout of the world’s principle producer and processor of medication used to treat malaria.
The operational assets are located in a central African country.
The firm supplies finished pharmaceuticals products (FPP) and active pharmaceutical ingredients (API) to the global pharmaceutical and food & beverage industry. Due to their advanced age, the European owners of the company decided to cede the business, which is the only pharmaceutical enterprise in Africa that produces these medicinal products to the shelf from natural resources and with full-fledged manufacturing facilities.
Ticket size: USD 10 – 15 MM
Hello 248,
No News so far.
Regards!
Dear 232,
Any feedback from your contact with respect to this opportunity?
Best
Thank you for the information. I will get back ASAP.
Good day,
In terms of certification, it is GMP certified and WHO recognised. The infrastructure are good and all export goods are air-shipped.
Regards
Hello again. We need some more specific information.
– is the structure registered with the local authorities?
– is quality control in place? any certification, what level?
– does the product have a patent? national / international registration?
– what are the product’s active ingredients?
– how is the internal and external infrastructure? (water, sewage, roads)
– what is the demand? regional, continental?
– how many local employees and how many in Luxembourg?
Operations in Congo DRC, with holding company in Luxembourg. It is an equity deal in Luxembourg.
Thank you for your quick reply.
Would it be possible to specify the Central African country where it is based?